UCB SA (UCBJF)
USD 150.7
(-5.46%)
USD 150.7
(-5.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.18 Billion EUR | -4.8% |
| 2022 | 5.51 Billion EUR | -4.5% |
| 2021 | 5.77 Billion EUR | 8.04% |
| 2020 | 5.34 Billion EUR | 8.83% |
| 2019 | 4.91 Billion EUR | 6.07% |
| 2018 | 4.63 Billion EUR | 2.25% |
| 2017 | 4.53 Billion EUR | 8.43% |
| 2016 | 4.17 Billion EUR | 7.79% |
| 2015 | 3.87 Billion EUR | 15.91% |
| 2014 | 3.34 Billion EUR | -1.96% |
| 2013 | 3.41 Billion EUR | -1.47% |
| 2012 | 3.46 Billion EUR | 6.65% |
| 2011 | 3.24 Billion EUR | 0.87% |
| 2010 | 3.21 Billion EUR | 3.27% |
| 2009 | 3.11 Billion EUR | -13.47% |
| 2008 | 3.6 Billion EUR | -0.69% |
| 2007 | 3.62 Billion EUR | 43.72% |
| 2006 | 2.52 Billion EUR | 7.77% |
| 2005 | 2.34 Billion EUR | -33.76% |
| 2004 | 3.53 Billion EUR | 6.21% |
| 2003 | 3.32 Billion EUR | -40.99% |
| 2002 | 5.63 Billion EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.39 Billion EUR | -47.6% |
| 2024 Q2 | 1.39 Billion EUR | 0.0% |
| 2023 Q3 | 1.33 Billion EUR | -48.57% |
| 2023 Q1 | 1.25 Billion EUR | -51.41% |
| 2023 FY | 5.25 Billion EUR | -4.8% |
| 2023 Q4 | 2.66 Billion EUR | 100.0% |
| 2023 Q2 | 2.58 Billion EUR | 105.56% |
| 2022 Q4 | 2.59 Billion EUR | 0.0% |
| 2022 Q2 | 2.92 Billion EUR | 104.9% |
| 2022 Q1 | 1.42 Billion EUR | -52.4% |
| 2022 FY | 5.51 Billion EUR | -4.5% |
| 2021 FY | 5.77 Billion EUR | 8.04% |
| 2021 Q4 | 2.99 Billion EUR | 100.0% |
| 2021 Q3 | 1.49 Billion EUR | -46.02% |
| 2021 Q2 | 2.77 Billion EUR | 100.0% |
| 2021 Q1 | 1.38 Billion EUR | -49.29% |
| 2020 Q2 | 2.6 Billion EUR | 100.0% |
| 2020 Q4 | 2.73 Billion EUR | 100.0% |
| 2020 Q1 | 1.3 Billion EUR | -49.65% |
| 2020 FY | 5.34 Billion EUR | 8.83% |
| 2020 Q3 | 1.36 Billion EUR | -47.49% |
| 2019 Q4 | 2.59 Billion EUR | 0.0% |
| 2019 FY | 4.91 Billion EUR | 6.07% |
| 2019 Q1 | 1.16 Billion EUR | 0.0% |
| 2019 Q2 | 2.32 Billion EUR | 100.0% |
| 2018 Q2 | 1.13 Billion EUR | 0.0% |
| 2018 FY | 4.63 Billion EUR | 2.25% |
| 2018 Q1 | 1.13 Billion EUR | -1.35% |
| 2017 FY | 4.53 Billion EUR | 8.43% |
| 2017 Q2 | 1.08 Billion EUR | 0.0% |
| 2017 Q1 | 1.08 Billion EUR | 1.07% |
| 2017 Q4 | 1.15 Billion EUR | 0.0% |
| 2017 Q3 | 1.15 Billion EUR | 5.8% |
| 2016 Q1 | 998 Million EUR | 1.89% |
| 2016 FY | 4.17 Billion EUR | 7.79% |
| 2016 Q3 | 1.07 Billion EUR | 7.77% |
| 2016 Q4 | 1.07 Billion EUR | 0.0% |
| 2016 Q2 | 998 Million EUR | 0.0% |
| 2015 Q4 | 979.5 Million EUR | 0.0% |
| 2015 Q1 | 958.5 Million EUR | 9.36% |
| 2015 Q2 | 958.5 Million EUR | 0.0% |
| 2015 Q3 | 979.5 Million EUR | 2.19% |
| 2015 FY | 3.87 Billion EUR | 15.91% |
| 2014 Q1 | 795.5 Million EUR | 7.79% |
| 2014 Q3 | 876.5 Million EUR | 10.18% |
| 2014 Q2 | 795.5 Million EUR | 0.0% |
| 2014 Q4 | 876.5 Million EUR | 0.0% |
| 2014 FY | 3.34 Billion EUR | -1.96% |
| 2013 Q3 | 738 Million EUR | -10.92% |
| 2013 Q1 | 828.5 Million EUR | 0.0% |
| 2013 FY | 3.41 Billion EUR | -1.47% |
| 2013 Q4 | 738 Million EUR | 0.0% |
| 2013 Q2 | 828.5 Million EUR | 0.0% |
| 2012 FY | 3.46 Billion EUR | 6.65% |
| 2011 FY | 3.24 Billion EUR | 0.87% |
| 2010 FY | 3.21 Billion EUR | 3.27% |
| 2009 FY | 3.11 Billion EUR | -13.47% |
| 2008 FY | 3.6 Billion EUR | -0.69% |
| 2007 FY | 3.62 Billion EUR | 43.72% |
| 2006 FY | 2.52 Billion EUR | 7.77% |
| 2005 FY | 2.34 Billion EUR | -33.76% |
| 2004 FY | 3.53 Billion EUR | 6.21% |
| 2003 FY | 3.32 Billion EUR | -40.99% |
| 2002 FY | 5.63 Billion EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Qrons Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -268119.462% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -10616.797% |
| Adynxx, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -4114.59% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -30957.083% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -28344.396% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -6843172.939% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -786840.015% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -32753.611% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -29407992.617% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -24027.014% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -7883906.816% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -87700.746% |
| Marizyme, Inc. | 645.81 Thousand USD | -802303.184% |
| Genus plc | 668.8 Million USD | -674.821% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -2012.378% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -5234560.687% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -1263294.0% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -6750723.986% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -13112911.792% |
| MultiCell Technologies, Inc. | 49.32 USD | -10506893655.069% |
| ONE Bio Corp. | 52.29 Million USD | -9808.941% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -10322.156% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -10597037.014% |
| Q BioMed Inc. | 284.35 Thousand USD | -1822289.151% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -17408.531% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -3471.339% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -929056.73% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -7402757.143% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 64.724% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -518718618.719% |
| Enzolytics Inc. | 52.79 Thousand USD | -9815037.51% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -851467.314% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -322.566% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -3694941.428% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -839247.958% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | -517.251% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -519281.073% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -2190464.762% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -2190464.762% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -378424.47% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -1093772.037% |
| SYBLEU INC | 11.69 Thousand USD | -44305645.554% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -66429.721% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -39861438.462% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -13107604.76% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -155515.616% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -77649.437% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -498648.797% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -20010.995% |
| CSL Limited | 14.8 Billion USD | 64.986% |
| Cellectis S.A. | 755 Thousand USD | -686257.616% |